Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular Ketamine for Suicidal Patients in the Emergency Department
NCT07810023Enrolling by invitation
- Sponsor
- Endeavor Health
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of ketamine in suicidal ideation and major depressive disorder (MDD), sponsored by Endeavor Health. Primary endpoints: Difference in time spent in the Emergency Department up to 7 days, Average dosing participants' scores of investigator-developed feasibility and acceptability survey up to 7 days and 1 more. Started Sep 2026; status: enrolling by invitation.
02
Drugs
ketamine
03
Conditions
suicidal ideationmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07810023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07810023.